---
company: Evolent Health, Inc.
ticker: EVH
form: 8-K
filed: 2026-08-06
accession: 0001628908-26-000084
source: https://www.sec.gov/Archives/edgar/data/1628908/000162890826000084/
---

# Evolent Health (EVH) earnings release, August 6, 2026

Evolent Health, Inc. (EVH) · Form 8-K, Item 2.02 · Filed 2026-08-06 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1628908/000162890826000084/)

Evolent Announces Second Quarter 2026 Results

WASHINGTON (August 6, 2026) – Evolent Health, Inc. (NYSE: EVH) (“Evolent” or the “Company”), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2026.

Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, “We believe our results for the second quarter of 2026, our updated 2026 guidance and our 2027 outlook all demonstrate that Evolent is delivering strong growth, profitability and cash flow. We are confident in our emerging AI-led operational model that we believe allows us to deliver excellent client and clinical outcomes, while being highly disciplined with our cost structure."

Mario Ramos, Chief Financial Officer of Evolent stated, “Looking ahead to 2027, based on contracts in place today, upcoming launches scheduled and the strong continuing demand for our oncology solution, we expect to see revenue growth of over 25% compared to 2026. We expect the midpoint of our 2027 Adjusted EBITDA outlook will be at or above $150 million driven by expected improved Performance Suite care margins and a strong focus on expense reductions, despite significant continued industry headwinds from Medicaid and other client specific membership attrition. We also expect improved cash flow conversion, which, together with targeted debt reduction initiatives we are currently evaluating, we believe provides a clear path to addressing our capital structure and enhancing financial flexibility."

Highlights include (dollars in thousands, except for average PMPM fees and revenue per case):¹

The rising medical costs impacting health plans continue to drive robust demand for Evolent’s complex specialty care solutions.

Evolent has two partnership announcements, bringing the year-to-date total to four:

• First, we are preparing for the go live of an Oncology Performance Suite partnership with an existing advanced imaging client. The partnership will cover approximately 1.5 million lives across Medicaid and Medicare populations spread through 11 states. We currently expect this business to launch by December 2026, subject to certain regulatory approvals, and generate approximately $300 million in annualized revenue. As with other recent Performance Suite arrangements, this relationship includes Evolent’s full enhanced contractual protections.

• Second, an existing Specialty Technology & Services Suite client, a regional Blues plan customer, has signed an agreement to broaden its use of our Specialty Technology & Services Suite by adding new products and extending existing solutions to additional populations. We expect these implementations to occur during the third and fourth quarters of this year and annualized revenue from this contract to be less than $5 million.

Financial Results of Evolent Health, Inc.

In our earnings releases, prepared remarks, conference calls, slide presentations and webcasts, we may use or discuss financial measures not prepared in accordance with generally accepted accounting principles (“GAAP”). Definitions of the non-GAAP financial measures as well as reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are presented herein. See “Non-GAAP Financial Measures” for more information.

Reported Results

Evolent Health, Inc. reported the following results in accordance with GAAP (dollars in thousands, except for per share data):

Total cash and cash equivalents was $115.7 million as of June 30, 2026.

Adjusted Results

Evolent Health, Inc. reported the following adjusted results (dollars in thousands, except for per share data):²

Business Outlook

The Company does not believe it can meaningfully reconcile guidance for non-GAAP Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. because the Company cannot provide guidance for the more significant reconciling items between net income (loss) attributable to common shareholders of Evolent Health, Inc. and Adjusted EBITDA without unreasonable effort. This is due to the fact that future period non-GAAP guidance includes adjustments for items not indicative of our core operations, and as a result from changes to our business due to transactions and other events. Such items may, from time to time, include change in tax receivable agreement liability, other refinancing fees, gain (loss) from equity method investees, gain (loss) on repayment/extinguishment of debt, other income (expense), gain (loss) on disposal of non-strategic assets, goodwill impairments, right-of-use asset impairments, gain (loss) on lease terminations, stock-based compensation expense, severance costs and transaction-related costs. Such adjustments may be affected by changes in ongoing assumptions, judgments, as well as nonrecurring, unusual or unanticipated charges, expenses or gains (losses) or other items that may not directly correlate to the underlying performance of our business operations. The exact amount of these adjustments is not currently determinable but may be significant.

Full Year 2026 Guidance

Incorporating its year-to-date performance, the Company is raising its 2026 revenue guidance range to $2.6 to $2.7 billion. The Company also tightening its Adjusted EBITDA range to $120 to $135 million.

Additional Outlook Information

The Company expects to deploy $25 million to $30 million in cash for capitalized software development during 2026.... (truncated)ge Commission (“SEC”).

Web and Conference Call Information

Evolent Health, Inc. will hold a conference call to discuss its financial performance and related matters this morning, August 6, 2026, at 8:00 a.m., Eastern Time. To listen to a live broadcast via the internet and view the accompanying materials, please visit the Company's Investor Relations website at http://ir.evolent.com. To participate by telephone, dial (855) 940-9467, or (412) 317-6034 for international callers, and ask to join the “Evolent Health call.” Participants are advised to dial in at least fifteen minutes prior to the call to register. The call will be archived on the Company's website for one week and will be available beginning later this evening. Evolent invites all interested parties to attend the conference call.

About Evolent

Evolent specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolent.com.³

Contacts: investorrelations@evolent.com

Definitions

Revenue Agreements

Evolent reports the number of new revenue agreements signed for Performance Suite, Specialty Technology and Services Suite, Administrative Services and Case-based products. A new revenue agreement includes incremental revenue to the Company reflecting contracts for services to both new partner entities, corporations or health plans as well as additional sales to existing partners. New revenue agreements may include incremental services, geographic, or line of business expansions or a combination thereof. The conversion of Specialty Technology and Services Suite contracts to Performance Suite are also included in this definition. The Company does not count renewals for existing scope, growth of membership within an existing contract scope or transaction-related purchase agreements, if applicable, in this metric.

Lives on Platform and Per Member Per Month (“PMPM”) Fee

Performance Suite Lives on Platform are calculated by summing monthly members covered for specialty care services for contracts not under ASO arrangements divided by the number of months in the period. Specialty Technology and Services Suite Lives on Platform are calculated by summing monthly members covered for oncology, cardiology, musculoskeletal, advanced imaging and other diagnostic specialty care services for contracts under ASO arrangements divided by the number of months in the period. Administrative Services Lives on Platform are calculated by summing monthly members covered for administrative services implementation and core performance services divided by the number of months in the period. Cases are calculated by summing the number of individuals receiving services through our surgery management and advanced care planning programs in a given period. Members covered for more than one category are counted in each category.

Performance Suite Average PMPM fee is defined as revenue pertaining to our Performance Suite during the period reported divided by Performance Suite Lives on Platform for the period divided by the number of months in the period. Specialty Technology and Services Suite Average PMPM fee is defined as revenue pertaining to the Specialty Technology and Services Suite during the period reported divided by Specialty Technology and Services Suite Lives on Platform for the period divided by the number of months in the period. Administrative Services Average PMPM fee is defined as revenue pertaining to the Administrative Services during the period reported divided by the Administrative Services Lives on Platform for the period divided by the number of months in the period. Revenue per Case is calculated by the revenue pertaining to surgery management and advanced care planning programs divided by the number of cases for a given period.

Average Unique Members are calculated by summing members covered by our Performance Suite, Specialty Technology and Services Suite and Administrative Services. In cases where partners cross between multiple solutions, we only capture members from the solution with the maximum number of members.

Management uses Lives on Platform, PMPM fees, Cases, Revenue per Case and Average Unique Members because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance.

Medical Expense Ratio

Medical Expense Ratio (“MER”) is a key performance indicator used by management for purposes of monitoring operating performance and is calculated as GAAP total claims incurred related to our specialty care management services solution divided by GAAP revenue related to our Performance Suite. Management believes MER is useful to investors because it provides insight into the efficiency with which medical costs are managed relative to revenue and helps identify trends in the underlying performance. For periods prior to the consummation of the sale of Evolent Care Partners (“ECP”) in December 2025, we present non-GAAP MER excluding revenues from ECP because is not indicative of ongoing operations.⁴

## Financial statements

### Income Statement (For the Three Months Ended June 30, — Highlights include (dollars in thousands, except for average PMPM fees and revenue per case):)

| | For the Three Months Ended June 30, – 2026 | For the Three Months Ended June 30, – 2025 |
|---|---:|---:|
| Financial Results: | Revenue | 652,520 | 444,328 |
| Financial Results: | Net loss attributable to common shareholders of Evolent Health, Inc. | -28,364 | -51,090 |
| Financial Results: | Net loss margin | -4.3 | -11.5 |
| Financial Results: | Adjusted EBITDA | 28,050 | 37,547 |
| Financial Results: | Adjusted EBITDA Margin | 4.3 | 8.5 |
| Average Lives on Platform/Cases by Product Type | Performance Suite | 6,715 | 6,490 |
| Average Lives on Platform/Cases by Product Type | Specialty Technology and Services Suite | 75,641 | 77,019 |
| Average Lives on Platform/Cases by Product Type | Administrative Services | 1,189 | 1,231 |
| Average Lives on Platform/Cases by Product Type | Cases | 12 | 13 |
| Average Lives on Platform/Cases by Product Type | Average Unique Members | 39,956 | 40,201 |
| Average PMPM Fees/ Revenue per Case by Product Type | Performance Suite | 24.05 | 13.76 |
| Average PMPM Fees/ Revenue per Case by Product Type | Specialty Technology and Services Suite | 0.34 | 0.35 |
| Average PMPM Fees/ Revenue per Case by Product Type | Administrative Services | 13.46 | 15.13 |
| Average PMPM Fees/ Revenue per Case by Product Type | Cases | 3,608 | 2,969 |

### Income Statement (For the Three Months Ended June 30, — Evolent Health, Inc. reported the following results in accordance with GAAP (dollars in thousands, except for per share data):)

| | For the Three Months Ended June 30, – 2026 | For the Three Months Ended June 30, – 2025 |
|---|---:|---:|
| Revenue | 652,520 | 444,328 |
| Cost of revenue | 571,684 | 343,943 |
| Selling, general and administrative expenses | 68,831 | 75,209 |
| Net loss attributable to common shareholders of Evolent Health, Inc. | -28,364 | -51,090 |
| Net loss margin | -4.3% | -11.5% |
| Loss per share attributable to common shareholders of Evolent Health, Inc. | Basic and diluted | -0.25 | -0.44 |

### Income Statement (For the Three Months Ended June 30, — Evolent Health, Inc. reported the following adjusted results (dollars in thousands, except for per share data):)

| | For the Three Months Ended June 30, – 2026 | For the Three Months Ended June 30, – 2025 |
|---|---:|---:|
| Adjusted cost of revenue | 570,989 | 342,893 |
| Adjusted selling, general and administrative expenses | 53,481 | 63,888 |
| Adjusted EBITDA | 28,050 | 37,547 |
| Adjusted EBITDA margin | 4.3% | 8.5% |
| Adjusted income (loss) attributable to common shareholders | 2,226 | -11,013 |
| Adjusted income (loss) per share attributable to common shareholders: | Basic and diluted | 0.02 | -0.1 |

### Income Statement (For the Three Months Ended June 30, — (unaudited, in thousands, except per share data))

| | For the Three Months Ended June 30, – 2026 | For the Three Months Ended June 30, – 2025 | For the Six Months Ended June 30, – 2026 | For the Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenue | 652,520 | 444,328 | 1,148,766 | 927,977 |
| Expenses | Cost of revenue | 571,684 | 343,943 | 984,156 | 725,121 |
| Expenses | Selling, general and administrative expenses | 68,831 | 75,209 | 141,649 | 153,618 |
| Expenses | Depreciation and amortization expenses | 21,566 | 23,141 | 43,121 | 47,199 |
| Expenses | Loss on lease termination |  |  |  | 1,906 |
| Expenses | Change in fair value of contingent consideration |  | 3,206 |  | 2,926 |
| Expenses | Operating expenses | 662,081 | 445,499 | 1,168,926 | 930,770 |
| Expenses | Operating loss | -9,561 | -1,171 | -20,160 | -2,793 |
| Expenses | Interest income | 703 | 1,084 | 1,717 | 2,358 |
| Expenses | Interest expense | -16,859 | -11,601 | -33,727 | -21,986 |
| Expenses | Gain (loss) from equity method investees | -41 | 197 | -52 | 178 |
| Expenses | Loss on option exercise |  | -196 |  | -52,544 |
| Expenses | Extinguishment of Series A Preferred Stock and other refinancing fees |  | -9,000 |  | -9,000 |
| Expenses | Other income (expense), net | 109 | -35 | 851 | -83 |
| Expenses | Loss before income taxes | -25,649 | -20,722 | -51,371 | -83,870 |
| Expenses | Provision for (benefit from) income taxes | 2,715 | -825 | 3,625 | 645 |
| Expenses | Loss before preferred dividends and accretion of Series A Preferred Stock including excise tax | -28,364 | -19,897 | -54,996 | -84,515 |
| Expenses | Dividends and accretion of Series A Preferred Stock |  | -31,193 |  | -38,825 |
| Expenses | Net loss attributable to common shareholders of Evolent Health, Inc. | -28,364 | -51,090 | -54,996 | -123,340 |
| Loss per common share | Basic and diluted | -0.25 | -0.44 | -0.49 | -1.07 |
| Weighted-average common shares outstanding | Basic and diluted | 112,542 | 115,882 | 112,225 | 115,600 |
| Comprehensive loss | Net loss attributable to common shareholders of Evolent Health, Inc. | -28,364 | -51,090 | -54,996 | -123,340 |
| Other comprehensive loss, net of taxes, related to: | Foreign currency translation adjustment |  | 22 | -1,002 | 46 |
| Other comprehensive loss, net of taxes, related to: | Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. | -28,364 | -51,068 | -55,998 | -123,294 |

### Income Statement ((unaudited, in thousands))

| | Reconciliation of Adjusted Cost of Revenue to Cost of Revenue – For the Three Months Ended June 30, – 2026 | For the Three Months Ended June 30, – 2026 | Reconciliation of Adjusted Cost of Revenue to Cost of Revenue – For the Three Months Ended June 30, – 2025 | For the Three Months Ended June 30, – 2025 | Reconciliation of Adjusted Cost of Revenue to Cost of Revenue – For the Six Months Ended June 30, – 2026 | For the Six Months Ended June 30, – 2026 | Reconciliation of Adjusted Cost of Revenue to Cost of Revenue – For the Six Months Ended June 30, – 2025 | For the Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|---:|---:|---:|---:|
| Cost of revenue | 571,684 |  | 343,943 |  | 984,156 |  | 725,121 |  |
| Less: | Stock-based compensation | 695 |  | 1,050 |  | 1,214 |  | 1,707 |  |
| Less: | Adjusted cost of revenue | 570,989 |  | 342,893 |  | 982,942 |  | 723,414 |  |

### Income Statement (For the Three Months Ended June 30, — (unaudited, in thousands except MER percentages))

| | For the Three Months Ended June 30, – 2026 | For the Three Months Ended June 30, – 2025 | For the Six Months Ended June 30, – 2026 | For the Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenue | Performance Suite | 484,503 | 267,917 | 807,806 | 570,938 |
| Revenue | Specialty Technology and Services Suite | 78,161 | 81,401 | 158,960 | 164,222 |
| Revenue | Administrative Services | 47,989 | 55,880 | 97,576 | 113,071 |
| Revenue | Cases | 41,867 | 39,130 | 84,424 | 79,746 |
| Revenue | Total revenue | 652,520 | 444,328 | 1,148,766 | 927,977 |
| Less: | Revenue from Evolent Care Partners |  | 15,469 |  | 73,268 |
| Less: | Performance Suite revenue less revenue from Evolent Care Partners | 484,503 | 252,448 | 807,806 | 497,670 |
| Less: | Total claims incurred related to our specialty care management services solution | 461,520 | 214,247 | 763,297 | 420,239 |
| Less: | Medical expense ratio | 95.3 | 80 | 94.5 | 73.6 |
| Less: | Medical expense ratio excluding Evolent Care Partners | 95.3 | 84.9 | 94.5 | 84.4 |

### Income Statement (For the Three Months Ended June 30, — (unaudited, in thousands))

| | For the Three Months Ended June 30, – 2026 | For the Three Months Ended June 30, – 2025 | For the Six Months Ended June 30, – 2026 | For the Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Net loss attributable to common shareholders of Evolent Health, Inc. | -28,364 | -51,090 | -54,996 | -123,340 |
| Net loss margin | -4.3 | -11.5 | -4.8% | -13.3% |
| Less: | Interest income | 703 | 1,084 | 1,717 | 2,358 |
| Less: | Interest expense | -16,859 | -11,601 | -33,727 | -21,986 |
| Less: | Benefit from (provision for) income taxes | -2,715 | 825 | -3,625 | -645 |
| Less: | Depreciation and amortization expenses | -21,566 | -23,141 | -43,121 | -47,199 |
| Less: | Extinguishment of Series A Preferred Stock and other refinancing fees |  | -9,000 |  | -9,000 |
| Less: | Gain (loss) from equity method investees | -41 | 197 | -52 | 178 |
| Less: | Loss on option exercise |  | -196 |  | -52,544 |
| Less: | Change in fair value of contingent consideration |  | -3,206 |  | -2,926 |
| Less: | Other income (expense), net | 109 | -35 | 851 | -83 |
| Less: | Loss on lease termination |  |  |  | -1,906 |
| Less: | Stock-based compensation expense | -15,201 | -11,580 | -25,850 | -22,661 |
| Less: | Severance costs | -275 | -791 | -275 | -1,805 |
| Less: | Dividends and accretion of Series A Preferred Stock |  | -31,193 |  | -38,825 |
| Less: | Transaction-related costs | -569 |  | -1,031 | -703 |
| Less: | Adjusted EBITDA | 28,050 | 37,547 | 50,117 | 74,407 |
| Less: | Adjusted EBITDA margin | 4.3 | 8.5 | 4.4 | 8 |

### Income Statement (For the Three Months Ended June 30, — (unaudited, in thousands, except per share data))

| | For the Three Months Ended June 30, – 2026 | For the Three Months Ended June 30, – 2025 | For the Six Months Ended June 30, – 2026 | For the Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Net loss attributable to common shareholders of Evolent Health, Inc. | -28,364 | -51,090 | -54,996 | -123,340 |
| Less: | Loss from equity method investees | -41 | 197 | -52 | 178 |
| Less: | Other income (expense), net | 109 | -35 | 851 | -83 |
| Less: | Benefit from (provision for) income taxes | -2,715 | 825 | -3,625 | -645 |
| Less: | Change in fair value of contingent consideration |  | -3,206 |  | -2,926 |
| Less: | Extinguishment of Series A Preferred Stock and other refinancing fees |  | -9,000 |  | -9,000 |
| Less: | Loss on option exercise |  | -196 |  | -52,544 |
| Less: | Purchase accounting adjustments | -12,490 | -13,364 | -24,980 | -26,729 |
| Less: | Loss on lease termination |  |  |  | -1,906 |
| Less: | Stock-based compensation expense | -15,201 | -11,580 | -25,850 | -22,661 |
| Less: | Severance costs | -275 | -791 | -275 | -1,805 |
| Less: | Transaction-related costs | -569 |  | -1,031 | -703 |
| Less: | Tax impact (1) | 592 | -2,927 | -7 | -948 |
| Less: | Adjusted income (loss) attributable to common shareholders | 2,226 | -11,013 | -27 | -3,568 |
| Loss per share attributable to common shareholders | Basic and diluted | -0.25 | -0.44 | -0.49 | -1.07 |
| Adjusted income (loss) per share attributable to common shareholders | Basic and diluted | 0.02 | -0.1 |  | -0.03 |
| Weighted-average common shares | Basic and diluted | 112,542 | 115,882 | 112,225 | 115,600 |

### Balance Sheet (June 30, 2026 — (in thousands, except share data))

| | June 30, 2026 – (unaudited) | December 31, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 115,703 | 151,856 |
| Current assets: | Restricted cash | 22,990 | 26,134 |
| Current assets: | Accounts receivable, net | 449,118 | 309,861 |
| Current assets: | Prepaid expenses and other current assets | 22,699 | 18,521 |
| Current assets: | Total current assets | 610,510 | 506,372 |
| Current assets: | Restricted cash | 2,773 | 2,706 |
| Current assets: | Investments and equity method investees | 8,764 | 8,966 |
| Current assets: | Property and equipment, net | 81,921 | 80,785 |
| Current assets: | Right-of-use assets - operating | 2,710 | 4,373 |
| Current assets: | Prepaid expenses and other noncurrent assets | 2,308 | 3,078 |
| Current assets: | Contract cost assets | 14,047 | 13,537 |
| Current assets: | Intangible assets, net | 554,427 | 584,937 |
| Current assets: | Goodwill | 694,434 | 694,482 |
| Current assets: | Total assets | 1,971,894 | 1,899,236 |
| Current liabilities: | Accounts payable | 38,823 | 59,776 |
| Current liabilities: | Accrued liabilities | 43,897 | 65,755 |
| Current liabilities: | Operating lease liability - current | 1,541 | 15,343 |

### Cash Flow (For the Six Months Ended June 30, — (unaudited, in thousands))

| | For the Six Months Ended June 30, – 2026 | For the Six Months Ended June 30, – 2025 |
|---|---:|---:|
| Cash Flows Used In Operating Activities | Loss before preferred dividends and accretion of Series A Preferred Stock | -54,996 | -84,515 |
| Adjustments to reconcile net loss to net cash and restricted cash used in operating activities: | Change in fair value of contingent consideration |  | 2,926 |
| Adjustments to reconcile net loss to net cash and restricted cash used in operating activities: | Loss (gain) from equity method investees | 52 | -178 |
| Adjustments to reconcile net loss to net cash and restricted cash used in operating activities: | Extinguishment of Series A Preferred Stock and other refinancing fees |  | 9,000 |
| Adjustments to reconcile net loss to net cash and restricted cash used in operating activities: | Loss on option exercise |  | 52,544 |
| Adjustments to reconcile net loss to net cash and restricted cash used in operating activities: | Depreciation and amortization expenses | 43,121 | 47,199 |
| Adjustments to reconcile net loss to net cash and restricted cash used in operating activities: | Stock-based compensation expense | 25,850 | 22,661 |
| Adjustments to reconcile net loss to net cash and restricted cash used in operating activities: | Deferred tax benefit | 2,970 | -570 |
| Adjustments to reconcile net loss to net cash and restricted cash used in operating activities: | Amortization of contract cost assets | 2,023 | 2,523 |
| Adjustments to reconcile net loss to net cash and restricted cash used in operating activities: | Amortization of deferred financing costs | 5,930 | 2,403 |
| Adjustments to reconcile net loss to net cash and restricted cash used in operating activities: | Loss on lease termination |  | 1,906 |
| Adjustments to reconcile net loss to net cash and restricted cash used in operating activities: | Right-of-use operating assets | 1,663 | 792 |
| Changes in assets and liabilities, net of acquisitions: | Accounts receivable, net and contract assets | -139,257 | 55,925 |
| Changes in assets and liabilities, net of acquisitions: | Prepaid expenses and other current and non-current assets | -4,031 | -1,803 |
| Changes in assets and liabilities, net of acquisitions: | Contract cost assets | -2,533 | -1,649 |
| Changes in assets and liabilities, net of acquisitions: | Accounts payable | -17,810 | 18,189 |
| Changes in assets and liabilities, net of acquisitions: | Accrued liabilities | -22,350 | -5,867 |
| Changes in assets and liabilities, net of acquisitions: | Operating lease liabilities | -15,194 | -20,973 |
| Changes in assets and liabilities, net of acquisitions: | Accrued compensation and employee benefits | -22,021 | 4,543 |
| Changes in assets and liabilities, net of acquisitions: | Deferred revenue | 5 | -174 |
| Changes in assets and liabilities, net of acquisitions: | Reserve for claims and performance-based arrangements | 186,202 | -131,454 |
| Changes in assets and liabilities, net of acquisitions: | Other long-term liabilities | 80 | 803 |
| Changes in assets and liabilities, net of acquisitions: | Net cash and restricted cash used in operating activities | -10,296 | -25,769 |
| Cash Flows Used In Investing Activities | Cash paid for asset acquisitions and business combinations |  | -56,047 |
| Cash Flows Used In Investing Activities | Return of equity method investments | 150 | 788 |
| Cash Flows Used In Investing Activities | Purchases of investments and contributions to equity method investees |  | -1,000 |
| Cash Flows Used In Investing Activities | Investments in internal-use software and purchases of property and equipment | -13,255 | -17,365 |
| Cash Flows Used In Investing Activities | Net cash and restricted cash used in investing activities | -13,105 | -73,624 |
| Cash Flows (Used In) Provided by Financing Activities | Changes in working capital balances related to claims processing | -3,143 | -44,754 |
| Cash Flows (Used In) Provided by Financing Activities | Payment of contingent consideration |  | -1,000 |
| Cash Flows (Used In) Provided by Financing Activities | Proceeds from issuance of long-term debt, net of offering costs |  | 221,000 |
| Cash Flows (Used In) Provided by Financing Activities | Repayment of debt | -10,000 | -62,500 |
| Cash Flows (Used In) Provided by Financing Activities | Payment of preferred dividends |  | -9,198 |
| Cash Flows (Used In) Provided by Financing Activities | Taxes withheld and paid for vesting of equity awards | -1,823 | -4,621 |
| Cash Flows (Used In) Provided by Financing Activities | Net cash and restricted cash (used in) provided by financing activities | -14,966 | 98,927 |
